The Nasdaq suspension is the dominant risk — monitor for any update on relisting timeline or alternative exchange listing. The operational turnaround (revenue growth, narrowing losses, H1 profitability guidance) is positive but secondary to the liquidity and visibility risk of OTC trading. Watch for Q2 2026 results in August to validate guidance.
Price Chart
Executive Summary
BIO-key reported Q1 2026 revenue of $2.15M (+34% YoY) and a net loss of $(0.15)/share, significantly missing the consensus EPS estimate of $(0.60) by 217%. Revenue beat the $2.2M consensus marginally. The company guided Q2 2026 revenue to ~$2.8M (+65% YoY) and expects H1 2026 profitability, but shares trade on OTC Markets following a Nasdaq suspension, creating material uncertainty.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $2.15M vs $2.2M consensus (in-line); EPS $(0.15) vs $(0.60) consensus (strong miss on GAAP basis)
- Net loss improved to $(165K) from $(737K) in Q1 2025, but EPS miss reflects reverse-split-adjusted share count of 1.07M vs 470K
- Guidance: Q2 2026 revenue ~$2.8M (+65% YoY); H1 2026 revenue ~$5M (+50% YoY); expects H1 2026 profitability
- Shares suspended from Nasdaq; now trading on OTC Markets under BKYI
- Cash and equivalents $2.25M; stockholders' equity $7.43M; book value ~$7.04/share
- Gross margin 82%; operating expenses down 4% YoY; operating loss narrowed to $(118K) from $(641K)
Financial Impact
Revenue beat consensus by ~2% but EPS missed by 217% on a GAAP basis; guidance implies 65% Q2 revenue growth but Nasdaq delisting risk overshadows operational improvement
Risk Factors
- Nasdaq delisting and OTC trading severely limit institutional ownership and liquidity
- EPS miss of 217% vs consensus signals potential accounting noise from reverse split or one-time items
- Going concern risk persists given history of losses and limited cash ($2.25M)
- Financial statements not yet reviewed by auditors — subject to revision
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296532 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | S-1 | $1.65 | awaiting T+60 | — | $2.73 (−65.76%) |
Oct 6, 2026 21d ago | DEFA14A | $1.76 | awaiting T+60 | — | $2.73 (+55.40%) |
Oct 6, 2026 21d ago | 8-K | $1.76 | awaiting T+60 | — | $2.73 (+55.40%) |
Oct 2, 2026 25d ago | 8-K | $1.93 | awaiting T+60 | — | $2.73 (−41.71%) |
Sep 29, 2026 28d ago | Press Release | $3.12 | awaiting T+60 | — | $2.73 (−12.34%) |
Aug 24, 2026 9w ago | DEFA14A | $2.97 | awaiting T+60 | — | $2.73 (+7.91%) |
Aug 14, 2026 10w ago | 8-K | $3.18 | awaiting T+60 | — | $2.73 (+13.99%) |
Aug 13, 2026 10w ago | Press Release | $3.18 | awaiting T+60 | — | $2.73 (−13.99%) |
Aug 10, 2026 11w ago | Press Release | $4.17 | awaiting T+60 | — | $2.73 (−34.41%) |
Jul 28, 2026 13w ago | Press Release | $4.25 $2.10 | ▼ −50.59% | ▼ −54.94% | $2.73 (−35.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers